345 related articles for article (PubMed ID: 30327313)
1. The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging.
Larimer BM; Bloch E; Nesti S; Austin EE; Wehrenberg-Klee E; Boland G; Mahmood U
Clin Cancer Res; 2019 Feb; 25(4):1196-1205. PubMed ID: 30327313
[TBL] [Abstract][Full Text] [Related]
2. Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes.
Goggi JL; Tan YX; Hartimath SV; Jieu B; Hwang YY; Jiang L; Boominathan R; Cheng P; Yuen TY; Chin HX; Tang JR; Larbi A; Chacko AM; Renia L; Johannes C; Robins EG
Mol Imaging Biol; 2020 Oct; 22(5):1392-1402. PubMed ID: 32705455
[TBL] [Abstract][Full Text] [Related]
3. Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer.
Goggi JL; Hartimath SV; Xuan TY; Khanapur S; Jieu B; Chin HX; Ramasamy B; Cheng P; Rong TJ; Fong YF; Yuen TY; Msallam R; Chacko AM; Renia L; Johannes C; Hwang YY; Robins EG
Mol Imaging Biol; 2021 Oct; 23(5):714-723. PubMed ID: 33713000
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B PET Imaging of the Innate Immune Response.
Capaccione KM; Doubrovin M; Bhatt N; Mintz A; Molotkov A
Molecules; 2020 Jul; 25(13):. PubMed ID: 32646038
[TBL] [Abstract][Full Text] [Related]
5. Examining Immunotherapy Response Using Multiple Radiotracers.
Goggi JL; Hartimath SV; Hwang Y; Tan YX; Khanapur S; Ramasamy B; Jiang L; Yong FF; Cheng P; Tan PW; Husaini MA; Yuen TY; Jieu B; Chacko AM; Larbi A; Renia L; Johannes C; Robins EG
Mol Imaging Biol; 2020 Aug; 22(4):993-1002. PubMed ID: 32006204
[TBL] [Abstract][Full Text] [Related]
6. Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
Larimer BM; Wehrenberg-Klee E; Caraballo A; Mahmood U
J Nucl Med; 2016 Oct; 57(10):1607-1611. PubMed ID: 27230929
[TBL] [Abstract][Full Text] [Related]
7. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Larimer BM; Wehrenberg-Klee E; Dubois F; Mehta A; Kalomeris T; Flaherty K; Boland G; Mahmood U
Cancer Res; 2017 May; 77(9):2318-2327. PubMed ID: 28461564
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive Detection of Immunotherapy-Induced Adverse Events.
Ferreira CA; Heidari P; Ataeinia B; Sinevici N; Sise ME; Colvin RB; Wehrenberg-Klee E; Mahmood U
Clin Cancer Res; 2021 Oct; 27(19):5353-5364. PubMed ID: 34253581
[TBL] [Abstract][Full Text] [Related]
9. A Novel Translational PET Imaging Approach to Quantifying Distal Tumor Immune Activation After Targeted Radiation Therapy and Checkpoint Blockade.
Zhang Y; Deshane JS; Yang ES; Larimer B
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1217-1227. PubMed ID: 38199384
[TBL] [Abstract][Full Text] [Related]
10. Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.
Napier TS; Hunter CL; Song PN; Larimer BM; Sorace AG
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214172
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
12. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
13. Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma.
Goggi JL; Ramasamy B; Tan YX; Hartimath SV; Tang JR; Cheng P; Msallam R; Chacko AM; Hwang YY; Robins EG
Mol Imaging; 2021; 2021():9305277. PubMed ID: 35936114
[TBL] [Abstract][Full Text] [Related]
14. In vivo bioluminescence imaging of granzyme B activity in tumor response to cancer immunotherapy.
Chen M; Zhou K; Dai SY; Tadepalli S; Balakrishnan PB; Xie J; Rami FEI; Dai T; Cui L; Idoyaga J; Rao J
Cell Chem Biol; 2022 Oct; 29(10):1556-1567.e6. PubMed ID: 36103874
[TBL] [Abstract][Full Text] [Related]
15. Immunological and clinical implications of immune checkpoint blockade in human cancer.
Kim HD; Park SH
Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide.
de Aguiar Ferreira C; Heidari P; Ataeinia B; Sinevici N; Granito A; Kumar HM; Wehrenberg-Klee E; Mahmood U
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890355
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
19. Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Sabanathan D; Park JJ; Marquez M; Francisco L; Byrne N; Gurney H
Oncologist; 2017 Dec; 22(12):1470-1477. PubMed ID: 29146617
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
